This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Osaka University. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Innovations of Yoshiyuki Hari in Antisense Therapies
Introduction
Yoshiyuki Hari is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of molecular biology, particularly in the development of novel molecules for antisense therapies. His work focuses on creating molecules that can effectively regulate gene expression while being resistant to degradation.
Latest Patents
Yoshiyuki Hari holds a patent for a "Bridged artificial nucleoside and nucleotide." This invention aims to provide a new molecule that is not susceptible to nuclease degradation in vivo. It has a high binding affinity and specificity for target mRNAs, which allows for efficient regulation of specific genes. The novel artificial nucleoside features an amide bond introduced into a bridge structure of 2',4'-BNA/LNA. The oligonucleotide containing this bridged artificial nucleotide exhibits a binding affinity for single-stranded RNA comparable to known 2',4'-BNA/LNA, while also demonstrating increased nuclease resistance over LNA. This innovation is expected to have applications in nucleic acid drugs due to its stronger binding affinity for single-stranded RNAs compared to S-oligo's affinity.
Career Highlights
Yoshiyuki Hari is affiliated with Osaka University, where he continues to advance research in the field of molecular biology. His work has garnered attention for its potential impact on therapeutic strategies involving gene regulation.
Collaborations
Yoshiyuki has collaborated with notable coworkers, including Aiko Yahara and Satoshi Obika, who contribute to the research and development of innovative solutions in molecular therapies.
Conclusion
Yoshiyuki Hari's contributions to the field of antisense therapies through his patented innovations highlight the importance of developing effective and stable molecules for gene regulation. His work at Osaka University continues to pave the way for advancements in nucleic acid drugs.